Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uristat Plus is a combination nutraceutical product developed by Novogen Captab, specifically formulated to support urinary tract health and prevent recurrent urinary tract infections (UTIs). The formulation contains Cranberry Extract (200 mg), Potassium Magnesium Citrate (978 mg), and D-Mannose (300 mg). D-Mannose and Cranberry proanthocyanidins act as anti-adhesion agents that bind to the fimbriae of pathogenic bacteria like *Escherichia coli*, preventing them from attaching to the bladder wall and facilitating their clearance through urination. Potassium Magnesium Citrate acts as a urinary alkalinizer, helping to maintain an optimal urinary pH and reducing the acidity that can contribute to bladder irritation and the formation of certain types of kidney stones.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uristat Plus.